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Research ArticleHepatic cholesteryl ester accumulation in lysosomal acid
lipase deficiency: Non-invasive identification and
treatment monitoring by magnetic resonance
Peter E. Thelwall1,2,⇑, Fiona E. Smith1,2, Mark C. Leavitt3, David Canty3, Wei Hu3,
Kieren G. Hollingsworth1,2, Christian Thoma1, Michael I. Trenell1, Roy Taylor1,2,
Joseph V. Rutkowski3, Andrew M. Blamire1,2,, Anthony G. Quinn3,
1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; 2Newcastle Magnetic Resonance Centre, Newcastle
University, Newcastle upon Tyne, UK; 3Synageva BioPharma Corp., 128 Spring Street, Lexington, MA 02421, USABackground & Aims: Lysosomal Acid Lipase (LAL) deficiency is a
rare metabolic storage disease, caused by a marked reduction in
activity of LAL, which leads to accumulation of cholesteryl esters
(CE) and triglycerides (TG) in lysosomes in many tissues. We used
1H magnetic resonance (MR) spectroscopy to characterize the
abnormalities in hepatic lipid content and composition in
patients with LAL deficiency, and in ex vivo liver tissue from a
LAL deficiency rat model. Secondly, we used MR spectroscopy
to monitor the effects of an enzyme replacement therapy (ERT),
sebelipase alfa (a recombinant human lysosomal acid lipase),
on hepatic TG and CE content in the preclinical model.
Methods: Human studies employed cohorts of LAL-deficient
patients and NAFLD subjects. Rat experimental groups comprised
ex vivo liver samples of wild type, NAFLD, LAL-deficient, and LAL-
deficient rats receiving 4 weeks of sebelipase alfa treatment.
Hepatic 1H MR spectroscopy was performed using 3T (human)
and 7T (preclinical) MRI scanners to quantify hepatic cholesterol
and triglyceride content.
Results: CE accumulation was identified in LAL deficiency in both
human and preclinical studies. A significant decrease in hepatic
CE was observed in LAL-deficient rats following treatment with
sebelipase alfa.
Conclusions:We demonstrate an entirely non-invasive method
to identify and quantify the hepatic lipid signature associated
with a rare genetic cause of fatty liver. The approach provides a
more favorable alternative to repeated biopsy sampling forJournal of Hepatology 20
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Lysosomal Acid Lipase (LAL) deficiency is a rare autosomal reces-
sive lysosomal storage disease for which there is no currently
available effective treatment. The disease is caused by mutations
of the LIPA gene encoding the LAL enzyme and deficiency of this
enzyme leads to the accumulation of cholesteryl esters (CE) and
triglycerides (TG) in a number of tissues. Although a single dis-
ease, LAL deficiency presents as a clinical continuum with two
major phenotypes: the early onset phenotype is typically referred
to as Wolman Disease and the late onset phenotype is frequently
known as Cholesteryl Ester Storage Disease (CESD) [1]. Early
onset LAL deficiency typically presents in the first 6 months of life
and is the most rapidly fatal presentation. Growth failure associ-
ated with malabsorption, massive hepatosplenomegaly, rapidly
progressive liver dysfunction, and anaemia are the predominant
clinical features and key contributors to the early mortality. Sur-
vival beyond 1 year of age is highly unusual for these patients.
Late onset LAL deficiency is an underappreciated cause of cirrho-
sis in both children and adults, and is more heterogeneous with
respect to age of diagnosis. Elevation of serum transaminases,
hepatomegaly, and dyslipidemia (high LDL, high triglycerides,
and low HDL) are the important abnormalities. Disease complica-
tions include hepatic fibrosis with progression to cirrhosis and
accelerated atherosclerosis [2–5]. Diagnosis of late onset disease
requires a high index of clinical suspicion as the combination of
elevated transaminases, fatty liver, and dyslipidemia is also seen
in patients with the much more common diagnosis of metabolic
syndrome. In contrast to steatosis in patients with metabolic syn-
drome, which is primarily due to increased accumulations of TG,
steatosis in patients with LAL deficiency is associated with
increases in both CE and TG.13 vol. 59 j 543–549
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Monitoring liver lipid accumulation in patients has tradition-
ally involved analysis of biopsy samples. This approach is inva-
sive, carries an associated risk to the patient, and samples only
a small region of the organ and thus may be prone to sampling
errors. Magnetic resonance techniques can provide an alternative
to biopsy, offering a non-invasive, safe, and repeatable method to
measure liver lipid content and composition. MRI and 1H mag-
netic resonance (MR) spectroscopy methods are widely used in
research studies to measure hepatic lipid content, providing
either a measurement from a defined volume in the liver (via
PRESS spectroscopy [6]) or an image of lipid distribution (via
‘‘Dixon method’’ imaging [7]). A good correlation has been
observed between 1H MR measures of lipid content and biopsy
for steatosis [8,9]. 13C MR spectroscopy can also be used, and
has the advantage of providing more detailed information on
the chemical composition of hepatic lipids than obtained in 1H
spectroscopy [10]. In this study, we have employed 1H spectros-
copy to quantify and characterize the hepatic lipid signature
associated with a rare genetic defect of lipid metabolism in a
cohort of patients with LAL deficiency, and also utilized a bio-
chemical assay and 13C spectroscopy in the preclinical studies
to confirm that the observed changes in 1H spectra originate from
cholesterol/cholesteryl ester accumulation. The previously
described rat model of LAL deficiency develops liver abnormali-
ties that closely resemble the changes seen in patients with both
early and late onset LAL deficiency [11], showing CE and TG accu-
mulation in the liver, leading to rapid development of fibrosis in
this model and in other organs.
We hypothesized that the differences in lipid content and
composition resulting from LAL deficiency could be detected
non-invasively by MR spectroscopy, both in humans and in the
preclinical model. We hypothesised that a signature of LAL defi-
ciency could be identified (comprising detection of the increases
in hepatic CE and TG content), and that the reduction in hepatic
CE and TG content, following enzyme replacement therapy with
sebelipase alfa (Synageva BioPharma Corp., Lexington, MA,
USA), could be observed with these methods.
In addition to providing a method to monitor the efficacy of
therapies that target CE accumulation, the identification and
non-invasive quantification of hepatic CE content may allow for
the identification of patients with fatty liver who have increased
CE content and may warrant consideration for diagnostic testing
for LAL deficiency. Furthermore, a non-invasive method that
allows quantification of specific lipid species could help differen-
tiate patients with LAL deficiency from patients with non-alco-
holic fatty liver disease (NAFLD) due to metabolic syndrome.
With the recent progression of sebelipase alfa into clinical studies
for patients with LAL deficiency [12–14], such an approach would
also allow the non-invasive assessment of the effects of enzyme
replacement on lipid substrate accumulation in key tissues
including the liver in this disease.Materials and methods
Recruitment of human subjects
Study participants (n = 3) were patients with late onset LAL deficiency (also
known as Cholesteryl Ester Storage Disease) enrolled into the LAL-2-NH01 sub-
study in the UK [15]. This is a multicenter, prospective, observational study of a
subset of patients with late onset LAL to characterize clinical phenotype and dis-
ease progression. The patients’ diagnosis was confirmed by a previous diagnostic
test (i.e., documented decreased LAL activity relative to the normal range of the544 Journal of Hepatology 201lab performing the assay or molecular genetic testing confirming mutations con-
sistent with the diagnosis of LAL deficiency).
A comparator group of 1H spectroscopy datasets from NAFLD patients was
obtained from a previous 1H MR spectroscopy study performed at Newcastle Uni-
versity, where patients with NAFLD (defined as >5% intrahepatic lipid on 1H-MRS,
n = 5) were recruited from hepatology clinics within the Newcastle upon Tyne
Hospitals Foundation Trust.
Human magnetic resonance spectroscopy
MR data were acquired on a Philips 3T Achieva whole body scanner (Philips Med-
ical Systems, Best, The Netherlands) using a Philips 6-channel cardiac coil for 1H
imaging and spectroscopy. 1H spectroscopy comprised acquisition of PRESS-local-
ised spectra at six echo times (TR = 2.8 s, TE = 36, 50, 75, 100, 125, and 150 ms,
spectral width = 2 kHz, 2k data points) from a 3  3  3 cm voxel positioned in
the liver to avoid large vessels.
Analysis of human MR spectroscopy data
Spectra were processed using the Java-based magnetic resonance user interface
(jMRUI version 4.0) [16,17] using the AMARES non-linear least square fitting algo-
rithm [18] to determine peak areas. Resonances at 4.7, 1.3, and 0.9 ppm in 1H
spectra were quantified, which corresponded principally to protons in water, to
CH2 protons, and to CH3 protons, respectively. Initial attempts at determining
T2 of protons contributing to these peaks highlighted significant J-coupling effects
in lipid proton resonances at longer echo times. Thus no attempt was made to
correct for T2 differences between the resonances, and reported data originate
from the shortest echo time employed (36 ms).
Tissue fat fraction (v/v) calculations were performed using the widely-
employed method described by Longo et al. [8]. Since this approach does not dis-
tinguish between cholesterol and triglyceride, and is based on the assumption
that hepatic lipid has a normal (predominantly triglyceride) composition, a spec-
tral modelling approach was also employed to provide a quantitative measure of
hepatic cholesterol and fatty acid moiety content. The ratio of amplitudes of 1.3–
0.9 ppm 1H spectral resonances was used to determine the molar ratio of cho-
lesteryl to fatty acid moieties for each subject, and the ratio of 4.7–1.3 ppm res-
onances employed to quantify lipid content relative to water content. The model
assumed that the hepatic triglyceride composition, and thus its in vivo 1H spec-
trum, was identical to that observed experimentally and described in model form
by Hamilton et al. [19] (mean fatty acid chain length of 17.45 carbons, mean dou-
ble bond content of 1.92 per fatty acid moiety, and mean number of methylene-
interrupted double bonds of 0.32 per fatty acid moiety). The in vivo spectrum of
cholesterol moieties was assumed to be identical to the National Institute of
Advanced Industrial Science and Technology (Japan) database cholesterol 1H
spectrum [20]. Thus in the spectral model, triglyceride protons contribute to
1.3–0.9 ppm 1H spectral resonances at a ratio of 8.0:1 (as determined by Hamil-
ton et al. [19]) and cholesterol moieties contribute to these peaks at a ratio of
1:12.4. Molar ratio of fatty acid and cholesterol moieties was determined from
the experimentally measured ratio of 1.3–0.9 ppm peak amplitudes for each sub-
ject and then absolute concentrations of these components calculated using the
liver tissue water fraction, water and lipid proton density, and tissue density
assumptions described by Longo et al. [8].
Preclinical models of LAL deficiency and NAFLD
The rat model of LAL deficiency is a Donryu rat strain with a spontaneous deletion
at the 30 end of the LIPA gene, leading to deletion of 29 C-terminal amino acids
[21]. Rats were obtained through the National Bio Resource Project for the Rat
in Japan and maintained by breeding of heterozygous rats with the generation
of homozygous LAL deficient progeny. Genotyping was performed by PCR analysis
of DNA isolated from tail-clippings. 20–100 ng of CHELEX-extracted DNA [22]
was subjected to PCR using three primers: For1, 50-cagcacagggcacacacataggca-
30; Rev1, 50-ccacccttgtacagcataaaagac-30; and For2, 50-cagagacgcaggcacaataactcc-
30 for 33 cycles of: 45 s at 95 C, 45 s at 66 C, 1 min 30 s at 72 C. Reactions were
resolved on ethidium bromide-stained 1% agarose gels and alleles identified by
amplicons size; LAL+, 578 bp; LAL, 341 bp.
LAL deficient rats were housed at the Animal Resources Complex in the Col-
lege of Veterinary Medicine, University of Georgia, Athens, GA, USA, under the
supervision of the University of Georgia Institutional Animal Care and Use Com-
mittee. Rats were provided feed (Purina Lab Irradiated Rodent Chow #5053) and
water ad libitum. The three experimental groups comprised wild type (LAL+/+),
LAL deficient (LAL/) genotypes, and LAL deficient animals that had received
enzyme replacement therapy with sebelipase alfa. Rats were euthanized by CO23 vol. 59 j 543–549
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Fig. 1. Simulation data from spectral modelling and representative volume
localised 1H MR spectra acquired from study subjects. (A) Plot of the
relationship between the molar ratio of cholesterol to fatty acid moieties and
the ratio of CH3:CH2 peak amplitude. (B) 1H spectrum from a LAL deficient
subject; (C) 1H spectrum from a NAFLD subject. Signal from water protons at
4.7 ppm dominates the 1H spectra, and resonances from lipid CH2 and lipid and
cholesterol CH3 resonances are seen at 1.3 and 0.9 ppm, respectively. An elevation
in the ratio of CH3 to CH2 peak magnitude is observed in spectra from LAL
deficient patients due to accumulation of hepatic cholesterol ester.
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inhalation at 56 days of age. Harvested livers were frozen at 80 C for subse-
quent analysis by MR spectroscopy or enzymatic assay of total cholesterol and tri-
glyceride content.
A rat model of NAFLD was employed for comparison with the LAL deficient
rat liver, and was based on the model described by Kohli et al. [23]. Male Sprague
Dawley rats were housed at Newcastle University and provided with a high fat,
high carbohydrate diet for 8 weeks from an age of 5 weeks. Feed comprising
60% kcal from fat (TestDiet 58R2, IPS Product Supplies Limited, London, UK)
was supplied ad libitum, and drinking water was supplemented with 128 fructose
mM and 55 mM sucrose. Mice were euthanized and harvested livers frozen at
80 C for subsequent MR analysis.
Preclinical lysosomal acid lipase enzyme replacement therapy
LAL/ rats in the enzyme replacement therapy group received four weekly
doses of sebelipase alfa or vehicle from 4 weeks of age. Prior to dosing, rats were
pretreated with diphenhydramine (i/p, 5 mg kg1). Animals were then anesthe-
tized with isoflurane and sebelipase alfa (0.2 mg/ml in 0.9% saline) administered
intravenously via the tail vein at a dose of 3 mg kg1.
Preclinical magnetic resonance spectroscopy
All ex vivo MR spectra were acquired on a Varian 7T magnet and spectrometer
(DirectDrive system, Varian Inc, Palo Alto, CA) at Newcastle University. Frozen
liver samples (n = 6 for each group except NAFLD, where n = 3) were thawed
and warmed to 37 C, placed in 15 mm diameter plastic tubes and positioned
within a 25 mm diameter birdcage coil (Rapid Biomedical, Rimpar, Germany)
tuned to the 1H resonant frequency. Volume-localised 1H spectra were acquired
from a 15  15  15 mm voxel using a PRESS pulse sequence employing echo
times of 15 and 30 ms (TR = 10 s, spectral width = 4 kHz, 4096 data points, 4 aver-
ages). For collection of 13C spectra, liver samples were wrapped in thin plastic film
and placed directly upon a custom in-house 13C circular surface coil (15 mm
diameter) that was positioned above a 25  55 mm butterfly 1H decouple coil.
Natural abundance 13C spectra were collected using a pulse-acquire sequence
with 1HWALTZ decoupling (nominal tip = 90, spectral width = 10 kHz, repetition
time = 1.5 s, 1024 data points, 1000 averages).
Preclinical MR data analysis
1H datasets were processed using jMRUI 4.0 [24] using the AMARES non-linear
least square fitting algorithm [18] to determine peak areas of resonances at 4.7,
1.3, and 0.9 ppm, the mean T2 determined for each peak in each experimental
group by fitting a monoexponential function to the data. Signal amplitude at an
effective echo time of zero was determined, and these amplitudes analysed as
described for human studies to determine the relative molar ratio and the abso-
lute concentration of fatty acid and cholesterol moieties. Statistical significance of
differences in liver lipid and cholesterol concentration was assessed by one-way
ANOVA with post hoc Tukey multiple comparisons.
Biochemical assay of rat liver lipid content
Lipids were extracted from liver samples by grinding approximately 30 mg of tis-
sue in 600 ll of a 7:11:0.1 mixture of chloroform, isopropyl alcohol, and Igepal
CA-630. Samples were centrifuged, the supernatant collected and air dried at
50 C, then placed under vacuum for 30 min to remove the remaining solvent.
The remaining solids were resuspended in a solution of 1% Igepal CA-630 in
0.9% saline (w/v) and assayed for cholesterol content using a fluorimetric choles-
terol assay kit (Cayman Chemical, Ann Arbor, MI, USA) at dilutions 1:10, 1:100,
and 1:1000 according to the manufacturer’s instructions. Tissue cholesterol con-
tent was determined from sample dilutions that resulted in fluorescence mea-
surements within the assay kit standard curve.Results
Human studies
Fig. 1 shows spectralmodelling simulationdata and representative
human hepatic 1H spectra. Fig. 1A shows data from simulation
of mixtures of triglyceride and cholesterol, illustrating theJournal of Hepatology 201change in the ratio of 1.3:0.9 ppm peak resonance amplitudes as
molar fractional ratio of cholesterol increases. Cholesterolmoieties
contain five methyl groups with 1H resonances between 0.7 and
1.1 ppm (originating from the 18, 19, 21, 26, and 27 position
carbons of cholesterol), and thus gives a strong resonance in this
region of the 1H spectrum compared to a fatty acid moiety, which
contains one methyl group per molecule.
Fig. 1B and C show representative 1H spectra acquired from a
patient with LAL deficiency and from a patient with NAFLD. The
spectra are dominated by signal from water at 4.7 ppm, and lipid
and cholesterol CH2 and CH3 proton resonances are clearly seen
at 1.3 and 0.9 ppm, respectively. The ratio of peak areas for the
1.3 and 0.9 ppm resonances in NAFLD subjects is 0.11 ± 0.05:1,
in good agreement with the expected ratio of CH2:CH3 content
in hepatic 1H spectra [19] and reflecting a lipid composition dom-
inated by triglycerides [19]. In contrast, 1H spectra from LAL defi-
cient subjects show a mean ratio of these peak areas of
0.69 ± 0.11:1, reflecting marked elevation of signal from choles-
terol moieties. Table 1 shows cholesterol and fatty acid moiety
concentrations as determined from the three LAL deficient and
five NAFLD subjects. LAL deficient patients had a mean choles-
terol moiety concentration of 21.1 ± 13.6 mM, and a mean fatty
acid moiety concentration of 51.2 ± 19.2 mM. This contrasts
sharply with NAFLD subjects, who had a mean fatty acid moiety3 vol. 59 j 543–549 545
Table 1. Hepatic lipid content and cholesterol and fatty acid moiety concentration measurements determined for the LAL deficient and NAFLD cohort subjects. An
elevation in the ratio of cholesterol to fatty acid moiety content is observed in LAL deficient compared to NAFLD patients.
Volunteer Phenotype Lipid content
(% v/v)
Fatty acid moiety 
content (mM)
Cholesterol moiety 
content (mM)
Cholesterol:fatty acid 
moiety ratio
1 3.3 46 11.2 0.24
2 7.6 72 36.0 0.50
3 3.4 35 15.1 0.43
4 NAFLD 17.5 388 Not detected 0.00
5 NAFLD 9.6 210 2.1 0.01
6 NAFLD 24.6 534 Not detected 0.00
7 NAFLD 27.6 637 Not detected 0.00
8 NAFLD 19.5 406 9.9 0.02
LAL deficient
LAL deficient
LAL deficient
Research Articleconcentration of 442 ± 164 mM (corresponding to a triglyceride
content of 147 ± 55 mM). There is a marked difference in ratio
of cholesterol to fatty acid moiety content between the groups,
cholesterol was detected in only two of the five NAFLD patients
and in those the content was small relative to the fatty acid moi-
ety content. It is likely that small differences between the mea-
sured CH3:CH2 ratio and that predicted by the spectral model
for 100% triglyceride content may account for the calculated cho-
lesterol content in the NAFLD group. The differences between
subject groups were statistically significant for both cholesterol
and fatty acid moiety content (Mann-Whitney U test, p <0.05).
The strong 0.9 ppm signal arising from cholesterol moieties
facilitates detection of CE by 1H spectroscopy, and the markedly
different and characteristic pattern of lipid proton resonances
in the 1H spectrum from LAL deficient subjects compared to
the NAFLD group represents a biomarker with potential for
non-invasive diagnosis and monitoring of disease progression.
Preclinical studies
Fig. 2 shows 1H spectra acquired from the four preclinical exper-
imental groups (wild type, LAL deficient, sebelipase alfa-treated
LAL deficient rat liver, and a rat model of NAFLD), hepatic choles-
terol and fatty acid moiety concentration measurements (as
determined from the MR measurements) and a plot showing cor-
relation between MR and biochemical assay measurements of
hepatic cholesterol / cholesteryl ester content. As observed in
human 1H spectra, the preclinical MR spectra show resonances
from water protons (4.7 ppm) and lipid CH2 (1.3 ppm) and CH3
(0.9 ppm) protons, and the ratio of CH3 to CH2 proton resonances
differs between LAL deficient and NAFLD groups. Lipid reso-
nances are larger in LAL deficient and NALFD samples than in
the wild type group. ERT-treated LAL deficient rats show smaller
CH2 and CH3 resonances than their untreated counterparts, sim-
ilar to that of wild type rats.
Fig. 2E shows that a good correlation (R2 = 0.86) was observed
between biochemical assay and MR measurements of hepatic
cholesterol content, although absolute quantitation differed by
a factor of approximately two. We attribute this difference to
potential inaccuracies in the standard assumptions made in
quantitation of spectroscopy data [8] and/or to imperfect calibra-
tion of the biochemical assay kit.
As shown in Fig. 2F and G, LAL deficient rat liver shows a
marked elevation of hepatic cholesterol / cholesteryl ester
content (34.9 ± 18.6 mM compared to 0.8 ± 0.4 mM in wild type),546 Journal of Hepatology 201and also an increase in fatty acid moiety content (53.5 ± 30.6 mM
compared to 2.1 ± 2.4 mM in wild type) that we expect to be
principally due to accumulation of cholesteryl esters. In compar-
ison, the NAFLD group shows elevated fatty acid moiety content
(245 ± 139 mM) due to accumulation of triglycerides, but little
elevation in cholesterol content (1.4 ± 1.3 mM). The differences
between LAL deficient and NAFLD data mirror the differences
observed in our human studies.
Enzyme replacement therapy with sebelipase alfa resulted in
reduction in both cholesteryl and fatty acid moiety content (to
6.9 ± 4.1 mM and 14.8 ± 6.4 mM, respectively) compared to
untreated animals.
The fatty acid and cholesteryl moieties both contribute to the
1.3 and 0.9 ppm resonances in the 1H spectrum, so a resonance
uniquely attributable to cholesterol is not observed. However,
13C spectroscopy allows identification of resonances unique to
cholesteryl moieties, providing unequivocal evidence of choles-
terol accumulation in these samples that supports our conclu-
sions regarding the biochemical origins of the observed changes
in 1H spectra.
Fig. 3 shows representative 13C spectra from livers of wild
type, LAL deficient and sebelipase alfa-treated rats, and from a
solution of 1.2 M cholesterol dissolved in chloroform. Lipid reso-
nances dominate the spectrum with the largest peak at 30 ppm
corresponding to CH2 carbons in triglycerides, CE and phospho-
lipids. A number of peaks in the 13C spectrum can be assigned
as originating from the cholesterol group of CE, with the C18 res-
onance at 11.8 ppm (highlighted) providing a distinct and well-
resolved peak separate from other resonances in the spectrum.
This resonance and the resonance arising from fatty acid methyl
carbons (14.1 ppm, highlighted) each originates from a single
atom within their respective moieties (as opposed to the lipid
CH2 resonance at 30 ppm, for example). Elevation of cholesteryl
moiety content is observed in LAL deficient liver samples com-
pared to wild type, and reduced in sebelipase alfa-treated liver.
Fig. 4A–C shows the physical appearance of excised rat livers
from wild type, LAL deficient, and LAL deficient sebelipase alfa-
treated groups. In contrast to the normal dark red colour of livers
from wild type rats, LAL deficient livers have a pale orange/yel-
low colour resultant from lipid accumulation. In other experi-
ments, we have observed that the liver appearance of LAL
deficient rats is already abnormal at 4 weeks of age and becomes
more marked due to the increasing lipid content in LAL deficient
rats between 4 and 8 weeks of age (data not shown). Livers from
LAL deficient rats treated with sebelipase alfa showed a more3 vol. 59 j 543–549
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Fig. 2. 1HMR spectra acquired from ex vivo rat liver samples from four experimental groups, and cholesterol and fatty acid moiety content measurements. (A) Wild
type hepatic 1H spectrum; (B) LAL deficient hepatic 1H spectrum; (C) sebelipase alfa-treated LAL deficient hepatic 1H spectrum; (D) NAFLD hepatic 1H spectrum; (E)
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 Denotes a statistically significant difference compared to the other three groups (p <0.05). Elevated lipid resonances are observed in spectra from LAL deficient and NAFLD
rats compared to wild type, and sebelipase a-treated rats exhibit lower lipid content than their untreated counterparts. Elevation of CH3 to CH2 peak magnitude is observed
in spectra from LAL deficient rats compared to NAFLD rats due to accumulation of hepatic cholesteryl ester.
JOURNAL OF HEPATOLOGYnormal red colour that resembled the appearance of livers from
wild type rats. H&E and Oil Red-O stained histological sections
are shown in Fig. 4D–F and G–I, respectively. Oil Red-O stained
histological sections show elevated lipid density in LAL deficient
rat liver samples compared to wild type and sebelipase
alfa-treated rat liver samples.Discussion
We have used MR spectroscopy to characterize the lipid content
and composition in LAL deficient and NAFLD patients, and in liv-
ers from LAL deficient, NAFLD, wild type and sebelipase alfa-trea-
ted LAL deficient rats. We conclude that LAL deficiency is
associated with distinct 1H and 13C MR signatures arising from
cholesterol moieties, and that the 1H signature can be used to
identify and quantify abnormal lipid substrate content in patients
with LAL deficiency via this non-invasive method. Data from the
preclinical 1H spectroscopy studies mirrored findings from the
human 1H spectra: the ratio of 1H spectral resonances from CH2
and CH3 groups was substantially altered in LAL deficiency com-
pared to NAFLD. Preclinical 13C spectroscopy and biochemical
assay data provided confirmation that the alteration in lipid com-
position and content observed by 1H spectroscopy originated
from the expected accumulation of CE and TG (the normal sub-
strates for the deficient enzyme), with relative predominance of
CE to TG compared to wild type, consistent with earlier studies
in both patients with LAL deficiency and preclinical disease mod-
els [25–27].
1H spectroscopy is widely used in clinical research studies to
measure tissue lipid content, including hepatic lipid content [8],
and intra and extramyocellular lipid content in muscle [28].
Our preclinical results augment a previous report of mouse LAL
deficiency [29] which employed 1H MRI for non-invasiveJournal of Hepatology 201repeated measures of fat distribution and liver volume, though
this study did not differentiate between the different lipid com-
ponents in the LAL deficient mouse model. A range of methods
of calculating lipid content from 1H spectra have been reported
in the literature, including ratio of CH2 to water proton peak
intensities, correction of peak intensities for relaxation effects,
and quantitation of all visible lipid peaks in the spectrum
[19,30]. Our measurement of lipid content employs spectral mod-
elling to determine relative contributions of cholesteryl and fatty
acid moieties to the hepatic lipid MR signal. A limitation of our
approach is that the repetition time employed for 1H spectros-
copy in the human studies was insufficient to allow complete
T1 relaxation, and as a result our spectra may exhibit some T1
weighting. Differences in T1 between water and lipid components
would thus have the potential to influence results of lipid content
quantitation.
Based on hepatic lipid volume fraction, only one of the three
LAL deficient patients studied meet the criteria of NAFLD (>5%
intrahepatic lipid). Thus employing this widely-used hepatic ana-
lytical approach developed for assessing liver fat content in
NAFLD could result in failure to recognise hepatic lipid accumu-
lation in these patients. Our data thus demonstrate the impor-
tance of measuring CH3:CH2 peak ratio to assess hepatic lipid
composition.
Although the calculated hepatic cholesterol content was
markedly elevated in the LAL deficient patients compared to
NAFLD, the levels were lower than the levels seen in the preclin-
ical disease model. This most likely reflects differences in disease
severity between the rat model and these LAL deficiency patients,
though it is also possible that not all CH2 and CH3 protons were
visible in the MR spectra. Liver samples used in the preclinical
studies exhibited smaller proton CH2 and CH3 resonances at room
temperature after thawing from frozen, compared to when
scanned after warming to 37 C then cooled to room temperature3 vol. 59 j 543–549 547
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Fig. 3. 13C MR spectra acquired from ex vivo rat liver samples, and from a
solution of cholesterol in chloroform. (A) Wild type; (B) LAL deficient; (C)
sebelipase a-treated LAL deficient; (D) 1.2 M cholesterol dissolved in chloroform.
Resonances from the terminal methyl group of fatty acid chains (14.1 ppm) and
from the cholesterol-C18 resonance (11.8 ppm) are highlighted.
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Fig. 4. Physical and histological appearance of liver samples from wild type,
LAL deficient, and sebelipase a-treated LAL deficient rats. (A–C) Physical
appearance; (D–F) haematoxylin and eosin-stained histological sections; (G–I)
Oil Red-O-stained histological sections. (This figure appears in colour on
the web.)
Research Article(data not shown), illustrating the influence of lipid molecule
mobility on MR visibility. Further studies are required to investi-
gate whether there is potential for visibility to be affected in vivo
resulting from low lipid molecule mobility arising from the unu-
sual lipid composition and intracellular distribution associated
with LAL deficiency.
Our 13C preclinical data demonstrate an alternative measure
of hepatic cholesterol content via a resonance unique to choles-
terol moieties, but our attempts at translation to human studies
yielded spectra dominated by resonances from subcutaneous
lipid signals, masking any small 13C resonances from cholesterol
(data not shown). It is possible that 13C spectroscopy with
improved spatial localisation may allow detection of such reso-
nances in humans, though the 1H spectroscopy approach is sev-
eral orders of magnitude more sensitive than the 13C
measurements of hepatic CE due to the higher sensitivity of 1H
measurements, the 100% isotopic natural abundance of 1H (com-
pared to 1.1% for 13C), and the large number of methyl protons
contributing to the 1H CE signal at 0.9 ppm.
A good correlation was observed between MR and biochemi-
cal assay measurements of hepatic cholesterol content, and the
large relative differences in cholesterol and TG content observed
between LAL deficiency and NAFLD (human) or wild type (pre-
clinical) data underscore the potential of this approach for clinical
diagnosis or treatment monitoring.
Our enzyme replacement therapy data demonstrate reduction
of CE and TG substrate after treatment with sebelipase alfa. We
have previously established that sebelipase alfa corrects a num-
ber of clinically relevant abnormalities including growth failure,
hepatosplenomegaly, and transaminase elevations in the LAL
deficiency disease model [27,31]. The MR data demonstrates that
these improvements are associated with reduction in tissue CE
and TG content. The potential for 1H MR spectroscopy as a tool
for treatment monitoring in humans is apparent, providing a
non-invasive and repeatable measure of hepatic TG and CE con-548 Journal of Hepatology 201tent capable of being performed on the majority of clinical MR
scanners (unlike 13C spectroscopy, which requires additional
hardware and protocol development).
Our findings provide insights that may be applied to the iden-
tification of increased cholesteryl ester content in patients with
fatty liver which either represent undiagnosed cases of late onset
LAL deficiency or may be of interest as a potential covariate
impacting the risk of disease progression (given recent observa-
tions from disease models on the effects of increasing hepatic
cholesterol content on fibrosis progression [32,33]). Such an
approach demonstrates the value of MR spectroscopy as it allows
repeatable, non-invasive measurement of the concentration of a
metabolite central to the progression of a disease. Our findings
from this preclinical and human study thus demonstrate the
potential utility of our methods for monitoring of disease patho-
physiology and response to treatment using a novel diagnostic
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